ORIGIN Extension Data and What Happened After the Trial Ended

By
Published Updated Last reviewed
Clinical medical image for trials origin: ORIGIN Extension Data and What Happened After the Trial Ended

At a glance

| Parameter | Detail | |-----------|--------| | N | 12,537 (main trial); ~8 to 000 in extension | | Intervention | Insulin glargine titrated to FPG <95 mg/dL | | Comparator | Standard care | | Duration | Median 6.2 years (main); ~2.5 additional years (extension) | | Primary endpoint | Composite CV death, nonfatal MI, nonfatal stroke | | Key result | HR 1.02 (95% CI 0.94-1.11) for CV composite; 28% reduction in new-onset diabetes during active treatment; benefit lost post-cessation |

Why Extension Data Matters Here

The ORIGIN trial was designed to answer whether early insulin glargine could prevent cardiovascular events in people with dysglycemia (impaired fasting glucose, impaired glucose tolerance, or early type 2 diabetes) plus additional CV risk factors. The main trial ran from 2003 to 2011, reporting neutral CV outcomes and a 28% reduction in progression to overt diabetes among those with prediabetes at baseline.

But neutrality at 6 years does not guarantee neutrality at 10. And a 28% diabetes reduction during active treatment raises the question: does early insulin preserve beta-cell function, or does it merely suppress diagnostic glucose thresholds while the drug is on board?

The ORIGIN and Legacy Effects (ORIGINALE) extension study, published in 2014, attempted to answer these questions by following participants after trial completion.

The ORIGINALE Extension Design

After the main ORIGIN trial ended in February 2012, investigators invited all surviving participants to enter a passive observational follow-up. Key design elements:

  • No continued randomized treatment. Participants returned to their local physicians for standard diabetes care. Insulin glargine was discontinued in the intervention arm unless clinically indicated.
  • Endpoints tracked. The same composite CV endpoint (CV death, nonfatal MI, nonfatal stroke), all-cause mortality, new-onset diabetes, and cancer incidence.
  • Follow-up duration. Approximately 2.5 additional years of observation beyond the main trial, for a total of roughly 8.5-9 years from randomization.
  • Retention. Approximately 8,000 of the original 12,537 participants consented to extension follow-up. Loss was primarily due to death during the main trial, withdrawal, and site closures.

The extension was not powered independently. It was designed to detect legacy effects (persistent benefit or harm from the in-trial intervention period) rather than to test a new hypothesis.

What the Extension Showed

Cardiovascular Outcomes Remained Neutral

Extended follow-up confirmed the main trial finding. The original ORIGIN publication reported a hazard ratio of 1.02 (95% CI 0.94-1.11) for the primary CV composite. Through the extension period, no divergence of the Kaplan-Meier curves emerged. There was no late cardiovascular benefit and no late cardiovascular harm.

This finding is clinically important for two reasons. First, it rules out the theoretical concern that years of mild hyperinsulinemia from exogenous glargine might accelerate atherosclerosis over longer time horizons. Second, it confirms there is no delayed cardioprotective "legacy effect" analogous to what was seen with metformin in UKPDS post-trial monitoring.

Diabetes Prevention Did Not Persist

During the active treatment phase of ORIGIN, participants randomized to glargine who entered with prediabetes (IFG or IGT) had a 28% lower rate of progression to type 2 diabetes compared to standard care. This was a secondary outcome in the main trial.

In the extension, after glargine discontinuation, rates of new diabetes diagnosis converged between groups. The separation in cumulative diabetes incidence that had developed during the trial period did not widen further. Former glargine-treated participants developed diabetes at approximately the same rate as former standard-care participants once the intervention stopped.

The Regression Framework for Interpreting This Result:

| Phase | Glargine Arm | Standard Care Arm | Interpretation | |-------|-------------|-------------------|----------------| | In-trial (years 0-6.2) | 28% fewer new diabetes diagnoses | Reference | Drug effect: suppressed FPG below diagnostic threshold | | Post-trial (years 6.2-~9) | Convergence in new diagnosis rates | Reference | No durable disease modification | | Net legacy | No lasting separation |, | Early insulin did not preserve beta-cell mass or function long-term |

This pattern is consistent with what was observed in the DPP/DPPOS trial with troglitazone (benefit lost after drug withdrawal) and contrasts sharply with the durable effects of lifestyle intervention in DPP, where weight loss and exercise continued to reduce diabetes risk years after the active intervention ended.

Cancer and Mortality

The main ORIGIN trial was partially motivated by the 2009 controversy over whether insulin glargine might increase cancer risk. The original publication found no signal (HR 1.00 for any cancer), and the extension confirmed this null finding with additional person-years of follow-up. No site-specific cancer showed excess incidence in the glargine arm through 8+ years of observation.

All-cause mortality remained balanced between arms through the extension period. This is the longest controlled safety dataset for any basal insulin analog in a population with early dysglycemia.

Weight and Hypoglycemia: What Carried Forward

During the main trial, the glargine arm gained approximately 1.6 kg more than standard care and experienced more hypoglycemia (1.00 vs 0.31 events per 100 person-years for severe episodes). In the extension, after glargine discontinuation, weight differences narrowed and hypoglycemia rates equalized. Neither the weight gain nor the hypoglycemia risk produced lasting metabolic consequences detectable in the extension period.

Methodological Considerations

Strengths of the Extension

The ORIGINALE study had several methodological strengths worth noting:

  1. Large sample with long total follow-up. Even with attrition, ~8,000 participants over 8-9 total years provides substantial statistical power for major CV events.
  2. Clean washout. Because glargine was stopped in most participants, the extension provides a true test of legacy effects rather than ongoing drug exposure.
  3. Diverse population. ORIGIN enrolled across 40 countries, and the extension maintained geographic diversity.

Limitations

The extension also had important weaknesses:

  • Non-randomized observation. Post-trial treatment was at physician discretion. Participants in the former glargine arm may have been managed differently due to familiarity with insulin.
  • Attrition bias. The ~4,500 participants who did not enter the extension were older, sicker, and had more events during the trial. Their exclusion may bias toward null findings.
  • Insufficient power for subgroups. The extension could not reliably test whether specific subgroups (e.g., those with IFG only vs. early T2D) experienced differential legacy effects.
  • No mechanistic data. Beta-cell function (HOMA-B, C-peptide, disposition index) was not systematically measured in the extension, so the statement "no disease modification" rests on clinical glucose outcomes rather than direct physiological measurement.

Clinical Translation

What This Means for Prescribers

The ORIGIN extension data supports three practical conclusions:

First, basal insulin is cardiovascularly safe in early dysglycemia over long time horizons. Clinicians who initiate glargine in patients with early T2D and high CV risk are not adding cardiovascular hazard. This aligns with the FDA label for insulin glargine, which does not carry a CV warning.

Second, early basal insulin does not "cure" or durably modify prediabetes. The 28% diabetes reduction seen during active treatment was a pharmacological suppression of glucose, not a restoration of beta-cell capacity. This distinguishes insulin from lifestyle intervention and from certain pharmacological approaches (metformin in DPPOS showed modest persistent benefit).

Third, the weight gain and hypoglycemia from insulin glargine do not create lasting metabolic damage. While these are valid reasons to prefer other agents for diabetes prevention, they are reversible upon discontinuation.

Positioning Within Current Guidelines

The ADA Standards of Care (2024) does not recommend basal insulin for diabetes prevention. ORIGIN's extension data is one reason: the benefit does not persist. For established T2D, the ADA positions basal insulin as appropriate when other agents fail to achieve glycemic targets, and the ORIGIN CV safety data supports this positioning without the concern that early insulin exposure creates downstream harm.

The 2022 ADA/EASD consensus report on hyperglycemia management in T2D emphasizes cardioprotective agents (GLP-1 RAs, SGLT2 inhibitors) over insulin for patients with established CV disease. ORIGIN's neutral CV finding, while reassuring, means insulin glargine does not compete with agents that actively reduce CV events.

Comparison to Other Insulin CV Trials

| Trial | Insulin | Population | CV Finding | Legacy Effect | |-------|---------|-----------|-----------|---------------| | ORIGIN | Glargine | Early dysglycemia + CV risk | Neutral | None detected | | DEVOTE | Degludec vs glargine | T2D + high CV risk | Noninferior | Not tested | | FLAT-SUGAR | Glargine vs NPH+regular | T2D | Neutral glycemic variability | N/A (short trial) |

ORIGIN remains unique in testing insulin in prediabetes/early diabetes rather than established T2D, and in having long-term post-trial follow-up data.

The Bigger Question ORIGIN Raised

ORIGIN was conceived in an era when the "early insulin hypothesis" proposed that resting beta cells with exogenous insulin might preserve their function. The trial and extension together effectively refuted this hypothesis at the clinical level. Six years of maintaining fasting glucose below 95 mg/dL with glargine did not produce any detectable lasting benefit on glycemic trajectory.

This has shaped how the field thinks about disease modification in T2D. Glucose-lowering alone is necessary but insufficient. Agents that show durable benefits (tirzepatide in SURMOUNT, semaglutide in SELECT) appear to work through mechanisms beyond glucose suppression, including weight loss, inflammation reduction, and possibly direct effects on beta-cell stress.

Frequently asked questions

›
›
›
›
›
›
›
›
›
›

References

  1. ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367(4):319-328. https://pubmed.ncbi.nlm.nih.gov/22686416/
  2. ORIGIN Trial Investigators. Cardiovascular and other outcomes postintervention with insulin glargine and omega-3 fatty acids (ORIGINALE). Diabetes Care. 2014;37(11):2970-2978. https://pubmed.ncbi.nlm.nih.gov/25150157/
  3. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes (UKPDS 80). N Engl J Med. 2008;359(15):1577-1589. https://pubmed.ncbi.nlm.nih.gov/18784090/
  4. Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications (DPPOS). Lancet Diabetes Endocrinol. 2015;3(11):866-875. https://pubmed.ncbi.nlm.nih.gov/25964225/
  5. American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes, 2024. Diabetes Care. 2024;47(Suppl 1). https://pubmed.ncbi.nlm.nih.gov/38078589/
  6. FDA. Lantus (insulin glargine) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021081s073lbl.pdf